# PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone

> **NCT02265406** · PHASE3 · COMPLETED · sponsor: **Poitiers University Hospital** · enrollment: 354 (actual)

## Conditions studied

- Early Ventilation Acquired Pneumonia in Brain Injured Patients

## Interventions

- **DRUG:** Anti-Infective Agents
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02265406
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2020-07-25
- **Final completion:** 2020-07-25
- **Target enrollment:** 354 (ACTUAL)
- **Last updated:** 2021-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02265406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02265406, "PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02265406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*